Larotrectinib companion diagnostic - Ventana Medical Systems

Drug Profile

Larotrectinib companion diagnostic - Ventana Medical Systems

Latest Information Update: 30 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ventana Medical Systems
  • Class Diagnostic agents
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 20 Mar 2017 Early research in Cancer (Diagnosis) in USA (unspecified route)
  • 20 Mar 2017 Loxo Oncology collaborates with Ventana Medical Systems (a member of the Roche Group) to develop and commercialise a pan-TRK immunohistochemistry (IHC) test as a companion diagnostic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top